• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Zimmer Biomet Holdings Inc.

    5/23/25 7:00:04 AM ET
    $ZBH
    Industrial Specialties
    Health Care
    Get the next $ZBH alert in real time by email
    SD 1 zbh-20250521.htm SD SD


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

    Specialized Disclosure Report

     

    ZIMMER BIOMET HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

     

    Delaware

     

    001-16407

     

    13-4151777

    (State or other jurisdiction of

    incorporation)

     

    (Commission File Number)

     

    (I.R.S. Employer

    Identification No.)

    345 East Main Street

    Warsaw, Indiana 46580

    (Address of principal executive offices) (Zip Code)

     

    Chad F. Phipps

    Senior Vice President, General Counsel and Secretary

    (574) 373-3333

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

    ☑

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended______ .

     

     


    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

    This Form SD of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for the reporting period from January 1, 2024 to December 31, 2024.

     

    Rule 13p-1 requires disclosure of certain information when a company manufactures or contracts to manufacture products and the minerals specified in the rule are necessary to the functionality or production of those products. The specified minerals are cassiterite, columbite-tantalite (coltan), gold, wolframite, or their derivatives, which are limited to tantalum, tin and tungsten (collectively, the “conflict minerals”).

     

    Conflict Minerals Disclosure

    We have adopted a policy statement on conflict minerals that is publicly available on our website at www.zimmerbiomet.com/corporate/suppliers.html.

     

    We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We have determined that certain of our products contain conflict minerals that are necessary to the functionality or production of those products (such minerals are referred to as “necessary conflict minerals”). We engaged iPoint, a third-party consultant, to assist with our reasonable country of origin inquiry and due diligence process for calendar year 2024. With the assistance of iPoint, we conducted a good faith inquiry of the supply base that was reasonably designed to determine whether any necessary conflict minerals contained in our products originated in the Democratic Republic of the Congo (“DRC”) or an adjoining country or were from recycled or scrap sources. As part of this inquiry, we conducted a supply chain survey of our direct suppliers using the iPoint Conflict Minerals Platform and the Conflict Minerals Reporting Template created and made available by the Responsible Minerals Initiative to collect sourcing information related to necessary conflict minerals in our products.

     

    Based on the results of our inquiry, we have reason to believe that some conflict minerals may have originated in the DRC or an adjoining country and may not be from recycled, scrap, or other country sources. Accordingly, we exercised due diligence on the source and chain of custody of such necessary conflict minerals, as described in the Conflict Minerals Report attached as Exhibit 1.01 to this Form SD.

     

    A copy of this Form SD, including the Conflict Minerals Report attached hereto as Exhibit 1.01, is publicly available on our website at www.zimmerbiomet.com (in the “Investors” section under the “Financial Information” caption and “SEC Filings” sub-caption).

     

    The content of any website referred to in this Form SD or the attached Conflict Minerals Report, and any information accessible through any such website, is included for general information only and is not incorporated by reference in this Form SD or the attached Conflict Minerals Report, nor deemed filed with the Securities and Exchange Commission.

     

    Item 1.02 Exhibit

     

    As specified in Section 3, Item 3.01, the Company is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

     

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01 Resource Extraction Issuer Disclosure and Report

     

    Not applicable

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

     

     

     

    Exhibit No.

     

    Description

     

     

    1.01

     

    Conflict Minerals Report of Zimmer Biomet Holdings, Inc.

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Date: May 23, 2025

     

     

     

    ZIMMER BIOMET HOLDINGS, INC.

     

     

    By:

     

    /s/ Chad F. Phipps

    Name:

     

    Chad F. Phipps

    Title:

     

    Senior Vice President, General Counsel and Secretary

     


    Get the next $ZBH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBH

    DatePrice TargetRatingAnalyst
    12/17/2024$125.00 → $128.00Neutral → Overweight
    Analyst
    9/10/2024Peer Perform
    Wolfe Research
    7/1/2024$140.00 → $115.00Overweight → Neutral
    Piper Sandler
    5/30/2024$129.00Neutral
    Goldman
    5/21/2024$150.00Hold → Buy
    Argus
    1/4/2024$135.00 → $125.00Outperform → In-line
    Evercore ISI
    10/20/2023$120.00Neutral
    ROTH MKM
    8/28/2023$139.00Neutral → Buy
    BTIG Research
    More analyst ratings

    $ZBH
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2025 Financial Results

      WARSAW, Ind., April 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Monday, May 5, 2025, at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so by

      4/10/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

      WARSAW, Ind., May 22, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 9:20 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet  Zimmer Biomet is a global medical technology leader with a comprehensive portfo

      5/22/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces First Quarter 2025 Financial Results

      First quarter net sales of $1.909 billion increased 1.1% and 2.3% on a constant currency1 basisFirst quarter diluted earnings per share were $0.91; adjusted1 diluted earnings per share were $1.81Company updates full-year 2025 reported revenue guidance to include the Paragon 28 acquisition and currency expectations, and full-year 2025 adjusted1 earnings per share guidance to include Paragon 28, currency and the impact from current tariff proposalsWARSAW, Ind., May 5, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2025.  The Company reported first quarter net sales of $1.909 billion, an increase of 1.1% ove

      5/5/25 6:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Completes Acquisition of Paragon 28

      Transaction Further Strengthens Company's Position in High-Growth Foot and Ankle Segment WARSAW, Ind., April 21, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. ("Zimmer Biomet"; NYSE and SIX: ZBH), a global medical technology leader, today announced it has completed the acquisition of Paragon 28, Inc. ("Paragon 28"), a leading medical device company focused exclusively on the fast-growing foot and ankle orthopedic space. "We look forward to building on the strong foundation set by Albert DeCosta and the Paragon 28 team and are excited to officially welcome them to the Zimm

      4/21/25 9:00:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    SEC Filings

    See more
    • SEC Form SD filed by Zimmer Biomet Holdings Inc.

      SD - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/23/25 7:00:04 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.

      SCHEDULE 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      5/6/25 4:46:12 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.

      10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)

      5/5/25 4:00:26 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Noor Jehanzeb

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/3/25 5:06:51 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Farrell Michael J.

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 8:40:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Begley Christopher B

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      4/2/25 4:11:50 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Zimmer Biomet upgraded by Analyst with a new price target

      Analyst upgraded Zimmer Biomet from Neutral to Overweight and set a new price target of $128.00 from $125.00 previously

      12/17/24 8:26:36 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Wolfe Research initiated coverage on Zimmer Biomet

      Wolfe Research initiated coverage of Zimmer Biomet with a rating of Peer Perform

      9/10/24 8:03:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously

      7/1/24 7:51:41 AM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Leadership Updates

    Live Leadership Updates

    See more
    • Zimmer Biomet Names Kristen Cardillo as Senior Vice President, Chief Communications Officer

      WARSAW, Ind., March 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Kristen Cardillo as Senior Vice President, Chief Communications Officer. Reporting to President and CEO Ivan Tornos, Ms. Cardillo will join the Company on March 10, 2025, to lead Zimmer Biomet's global communications strategy, enhancing engagement with key stakeholders and amplifying the Company's position as a leader in MedTech. "Kristen's expertise in shaping compelling corporate narratives and leading high-impac

      3/6/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Appoints Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer

      WARSAW, Ind., Feb. 27, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Jehanzeb Noor is joining the Company as Senior Vice President, Chief Strategy, Innovation and Business Development Officer. He will report to Ivan Tornos, President and CEO of Zimmer Biomet. In his new role, Mr. Noor will be responsible for leading strategy development and execution and all facets of M&A, including the integration for our pending acquisition of Paragon 28. In addition, he will have oversight of the research and

      2/27/25 7:30:00 AM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Zimmer Biomet Announces Upcoming Changes to Company's Board of Directors

      WARSAW, Ind., Feb. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chairman of the Board Christopher Begley will retire from the Board of Directors at the Company's annual meeting of stockholders on May 29, 2025, pursuant to the mandatory director retirement age in the Company's Corporate Governance Guidelines;President and CEO Ivan Tornos will become Chairman of the Board upon Mr. Begley's retirement; andMichael Farrell

      2/25/25 4:05:00 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jafry Syed A. bought $223,641 worth of shares (2,135 units at $104.75), increasing direct ownership by 111% to 4,060 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      11/13/23 4:02:02 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Begley Christopher B bought $117,114 worth of shares (1,000 units at $117.11), increasing direct ownership by 39% to 3,540 units (SEC Form 4)

      4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)

      9/29/23 4:05:41 PM ET
      $ZBH
      Industrial Specialties
      Health Care

    $ZBH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/14/24 1:22:34 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zimmer Biomet Holdings Inc.

      SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      11/13/24 1:44:56 PM ET
      $ZBH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Zimmer Biomet Holdings Inc.

      SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)

      2/14/24 10:02:59 AM ET
      $ZBH
      Industrial Specialties
      Health Care